Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers

Purpose: Several new treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) have been approved within the last years - among them cabazitaxel (CAB), abiraterone acetate, enzalutamide, and radium-223. The aim of this study was to assess factors predictive for effi...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Cancer
Päätekijät: Zschäbitz, Stefanie, Vallet, Sonia, Hadaschik, Boris, Debatin, Daniel, Fuxius, Stefan, Karcher, Andreas, Pahernik, Sascha, Spath, Cathleen, Duensing, Stefan, Jäger, Dirk, Hohenfellner, Markus, Grüllich, Carsten
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ivyspring International Publisher 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370494/
https://ncbi.nlm.nih.gov/pubmed/28367230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.17644
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia